Exact Sciences Corporation (EXAS) Price Target Analysis
Updated Jul 2, 2026
Analyst Rating: Buy
Based on 41 analysts0.1% Below Target
EXAS trades 0.1% below Wall Street's consensus target of $105.00.
Current Price$104.91
Average Target$105.00
Low$105.00
Median$105.00
High$105.00
Analyst Target Range
Forward P/E582.8x
(High Premium)
PEG Ratio—
Implied Growth+116.4%
(High Growth)
Analyst Spread0.0%
(High Agreement)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes EXAS achieves its forward estimates and maintains a stable P/E multiple of 582.8x. This scenario reflects the blended consensus of 41 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
EXAS Price Target Analysis
Updated July 8, 2026As of July 8, 2026, Exact Sciences Corporation (EXAS) has a Wall Street consensus price target of $105.00, based on estimates from 41 covering analysts. With the stock currently trading at $104.91, this represents a potential upside of +0.1%. The company has a market capitalization of $20.02B.
Analyst price targets range from a low of $105.00 to a high of $105.00, representing a 0% spread in expectations. The median target of $105.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 22 analysts rating the stock as a Buy or Strong Buy,17 rating it Hold, and 2 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, EXAS trades at a trailing P/E of -95.4x and forward P/E of 582.8x. Analysts expect EPS to grow +116.4% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+3.8%
Industry Consensus
Avg Forward P/E
25.5x
(Growth Premium)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 GHGuardant Health, Inc. | $21.6B | $162.92 | $152.93 | -6.1% | Buy | — | 30 |
 NTRANatera, Inc. | $40.3B | $281.27 | $261.00 | -7.2% | Buy | — | 27 |
 ILMNIllumina, Inc. | $29.1B | $191.76 | $156.27 | -18.5% | Buy | 36.6x | 50 |
 LHLabcorp Holdings Inc. | $23.4B | $283.86 | $311.33 | +9.7% | Buy | 15.8x | 35 |
 DGXQuest Diagnostics Incorporated | $23.5B | $212.38 | $220.57 | +3.9% | Hold | 19.8x | 34 |
 NEOGNeogen Corporation | $2.0B | $9.39 | $11.00 | +17.1% | Hold | 25.4x | 11 |
 CDNACareDx, Inc | $1.5B | $28.31 | $27.00 | -4.6% | Buy | 30.3x | 13 |
 TMOThermo Fisher Scientific Inc. | $192.0B | $516.62 | $592.45 | +14.7% | Buy | 20.8x | 42 |
 DHRDanaher Corporation | $137.4B | $194.19 | $230.89 | +18.9% | Buy | 23.0x | 43 |
 BIOBio-Rad Laboratories, Inc. | $7.9B | $292.50 | $321.67 | +10.0% | Buy | 32.4x | 14 |
EXAS — Frequently Asked Questions
Quick answers to the most common questions about buying EXAS stock.
What is the EXAS stock price target for 2026?
The consensus price target for EXAS is $105, close to the current price of $104.91 (0.1% implied move). Based on 41 analyst estimates, the stock appears fairly valued near current levels.
Is EXAS a buy, sell, or hold?
EXAS has a consensus rating of "Buy" based on 41 Wall Street analysts. The rating breakdown is predominantly bullish, with 22 Buy/Strong Buy ratings. The consensus 12-month price target of $105 implies 0.1% upside from current levels.
Is EXAS stock overvalued or undervalued?
At a forward P/E of 582.8333x, EXAS trades at a premium valuation. The consensus price target of $105 (0.1% upside) suggests analysts may view current valuations as stretched.
How high can EXAS stock go?
The most bullish Wall Street analyst has a price target of $105 for EXAS, while the most conservative target is $105. The consensus of $105 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover EXAS stock?
EXAS is heavily covered by Wall Street, with 41 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 22 have Buy ratings, 17 recommend Hold, and 2 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the EXAS stock forecast?
The 12-month EXAS stock forecast based on 41 Wall Street analysts shows a consensus price target of $105, with estimates ranging from $105 (bear case) to $105 (bull case). The median consensus rating is "Buy".
What is EXAS's forward P/E ratio?
EXAS trades at a forward P/E ratio of 582.8x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy EXAS stock?
EXAS appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $105 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do EXAS price targets vary so much?
EXAS analyst price targets range from $105 to $105, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $105 consensus represents the middle ground.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare